LGND Ligand Pharmaceuticals Incorporated
Company Analysis
Latest News
🟢 Ligand Pharmaceuticals is trading 4.8% up in pre-market as biotech ETF XBI gains 3.64%
Ligand Pharmaceuticals is trading at $320.99, up 4.76%, with the move appearing primarily sector-led. - Biotech ETF XBI was up 3.64% pre-market amid broad...
🟢 Ligand Pharmaceuticals rises 4.1% — Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Ligand Pharmaceuticals is trading 4% down today amid broader biotech-sector weakness
Ligand Pharmaceuticals is trading 4.01% down at $294.46, with sector weakness the most plausible explanation, though no direct causal link was established. -...
🟢 Ligand Pharmaceuticals Surges 4.08% Following Barclays 'Overweight' Rating and $345 Price Target
- Barclays initiated coverage on Ligand Pharmaceuticals (LGND) with an 'Overweight' rating and a $345 price target on September 25, 2026. - This positive...
Ligand Clears Key Endpoints in Phase 3 Trial for Rare Metabolic Disorder
Ligand Pharmaceuticals reported positive top-line results from its pivotal Phase 3 trial of a lead drug candidate for a rare metabolic disorder. The study met...
Ligand Announces Up to $47M Financing and Royalty Agreement with AvenCell Therapeutics
Ligand Pharmaceuticals has entered into a financing agreement to provide up to $47 million to AvenCell Therapeutics, a clinical-stage company developing CAR-T...
Ligand to Acquire XOMA for $739 Million, Doubling Its Development Pipeline
Ligand Pharmaceuticals will acquire biotech royalty aggregator XOMA Royalty for approximately $739 million in cash. Ligand will pay $39.00 per share for all...